BAGSVAERD, Denmark – Novo Nordisk plans to make its NovoPen 6 and NovoPen Echo available in key markets in early 2019. The company has also announced partnership agreements with Dexcom, Glooko and Roche to integrate its connected insulin pen technology into their digital health solutions. “Our non-exclusive partnership strategy allows us to integrate with the various digital platforms that people are already using to help manage their diabetes,” said Camilla Sylvest, executive vice president of commercial strategy and corporate affairs at Novo Nordisk, in a statement. “We firmly believe that this will help more people realize the full benefit of our innovative medicines and begin to ease the mental burden of diabetes treatment for those individuals.” Building on its existing work with IBM Watson Health and Glooko, Novo Nordisk aims to integrate insulin-dosing data from connected pen devices with open ecosystems and diabetes management solutions, such as data from continuous glucose monitoring systems and blood glucose meters. Beyond launching connected durable devices, Novo Nordisk also expects to deliver connectivity for its disposable, pre-filled injection pens later in 2019, said Sylvest.
MENLO PARK, Calif. – First Mile Care, a spinout of the Health2047 incubator, has raised $2 million in seed funding to continue developing a digital platform for prediabetes management.
The platform enables community-based peer-to-peer connection for chronic conditions and will give people living with prediabetes—higher-than-normal blood sugar level but not yet Type 2 diabetes—the ongoing support they need to make lifestyle decisions that can reverse prediabetes and reduce the risk that their condition will develop into Type 2 diabetes.
“Health2047 is committed to developing system-level solutions to healthcare’s biggest challenges,” said Lawrence Cohen, CEO of Health2047, in a statement. “With 84 million Americans living with prediabetes, our spin out of First Mile Care is a critical step toward transforming chronic care and saving the U.S. healthcare industry trillions of dollars.”
The First Mile Care platform is based on the proven National Diabetes Prevention Program developed by the Centers for Disease Control and Prevention, a coaching program shown to reduce the incidence of Type 2 diabetes.
“Fighting chronic disease requires starting with a scalable approach,” said Karl Ronn, founder and CEO of First Mile Care, in a statement.
First Mile Care is the second company in a year to spin out of Health2047, a Silicon Valley business formation and commercialization enterprise launched by the American Medical Association in 2016. Health2047’s first spin out, Akiri, is building a network that enables health information to move seamlessly and securely throughout the U.S. health care system.
“First Mile Care is addressing the shortcomings of a system designed for acute care delivery,” said Dr. James Madara, CEO of the American Medical Association, in a statement. “The AMA is excited by this scalable, on-demand approach to engaging the community, peers, physicians and technologists to transform chronic care in the United States.”
CHICAGO – The American Association of Diabetes Educators has been awarded a $2.6 million grant over three years by The Leona M. and Harry B. Helmsley Charitable Trust for its new DANA resource for diabetes educators and other health care professionals. DANA provides up-to-date diabetes device information and training, technology news, education and mobile app reviews. “Diabetes educators play an increasingly vital role in patient care,” said Gina Agiostratidou, Helmsley Type 1 diabetes program director, in a statement. “DANA will empower these individuals to increase adoption and optimal use of diabetes technology. This technology has and will continue to transform the lives of patients by making management easier and supporting better outcomes.”
BLOOMFIELD, Conn. – Cigna is expanding its Diabetes Prevention Program in collaboration with Omada Health, offering an expanded suite of personalized, user-friendly digital health tools to help people prevent the onset of diabetes and other chronic diseases.
The program will be available to Cigna’s national and regional employer clients starting in January 2019.
As part of the digital lifestyle program, participants enrolled in a Cigna-administered health plan will be encouraged to make sustainable behavior changes under the guidance of a personal health coach and with the support from a peer group.
“We are excited to expand our relationship with Omada and integrate their program into our full suite of health services that encourage individuals to focus on preventing serious health conditions,” said Dr. Alan Muney, chief medical officer and executive vice president at Cigna, in a statement. “This collaboration represents some of the most important aspects of successful health care delivery—simplicity and convenience with tangible results for individual customers, and a seamless, data-driven approach with proven results for employers.”
Individual customers will have access to a fully integrated experience, with the program synchronized with other Cigna health services, including a discount gym-membership program, Cigna Health Coaches and a myCigna mobile application. Cigna also offers employers the opportunity to provide incentive programs such as premium discounts or contributions to health savings accounts that reward progress.
Omada’s digital program provides early identification of eligible participants, personalized engagement strategies, ongoing support from professional health coaches who provide one-on-one support, peer group support to drive accountability and interactive lessons on nutrition, physical activity, stress management and time management. Each Omada group contains an average 24 participants who experience the program together, and offer encouragement and accountability. Participants also integrate smart technology, including a wireless scale, pedometer, and a mobile application to track food and activity.
“Our integration with Cigna is the deepest, most comprehensive work we’ve done with a partner,” said Sean Duffy, co-founder and CEO of Omada Health, in a statement. “We look forward to working together to deliver results on a broad scale.”
Before Cigna launched the program nationally, Cigna and Omada ran a series of pilot programs with several large employer clients that demonstrated positive results across a range of measures, including a sustained weight loss of 3.5% to 5% for participants; and $424 to $972 net medical cost savings for participants.
TAMPA, Fla. – Through a new partnership, health care providers using Mellitus Health’s Insulin Insights insulin titration service will now have access to real-time patient data from Smart Meter’s iGlucose cellular diabetes care solution to help calculate precise insulin dosing recommendations for patients. “We’re excited to combine the remote monitoring power of iGlucose’s easy-to-use solution with our software’s precision insulin dosing recommendations to bring better glycemic control to insulin-using people with diabetes,” said Josh Davidson, CEO of Mellitus Health, in a statement. A recent remote monitoring study using Mellitus Health’s Insulin Insight software showed a 2.4% drop in HbA1c in 180 days, with no change in patient lifestyle and no severe hypoglycemic events, Davidson said. Smart Meter’s iGlucose solution uses cell-enabled technology to automatically transmit real-time blood glucose results that can be viewed and acted on by a health care team. “Our partnership with Mellitus Health will undoubtedly alleviate hurdles, improve insulin titration recommendations and ultimately deliver better outcomes,” said Cliff McIntosh, CEO of Smart Meter, in a statement. “We are extremely proud of the role our iGlucose solution will play in improving diabetes management.”
NEW YORK – One Drop has expanded its Apple Watch diabetes management solution with a wireless blood glucose monitoring system that connects directly to Apple Watch, allowing users to accurately log, monitor and share their diabetes data and import other biometric telemetry straight into One Drop for diabetes management.
Previously, One Drop had launched a companion Apple Watch app to manually log blood glucose, food, medication and exercise moments, and view daily stats and goals. Now, One Drop gives users the option to seamlessly transfer blood glucose data from One Drop | Chrome directly to the Apple Watch companion app, making One Drop the first and only device to send blood glucose data directly to Apple Watch, said Jeff Dachis, CEO of One Drop, in a statement.
Apple Watch Bluetooth connectivity is the newest of thousands of One Drop integrations that allow users to pull their data from other apps and devices into One Drop | Mobile. The solution captures data from Apple HealthKit, Google Fit, Fitbit, Dexcom and Companion Medical’s InPen, among others. With the release of iOS 12, One Drop will further expand iOS integrations by launching Apple Health Records and Siri Shortcuts.
Users subscribed to One Drop | Experts can grant their coach permission to view vitals, labs and medications shared to Apple Health Records. Personalized Siri Shortcuts to log food moments and recall average blood glucose and percent in blood glucose range are also featured.
One Drop also recently announced One Drop | Automated Decision Support, which uses artificial intelligence to accurately provide forecasted blood glucose prediction values over time and provide behavioral recommendations based on those predictions. One Drop’s propriety AI generates accurate predictions for a single user based on over 1.3 billion aggregate longitudinal diabetes health data of all people utilizing the One Drop platform. The service will be offered to free mobile users later this month.
“For too long the diabetes industry has operated on point solutions and closed systems focused on the needs of healthcare providers in the clinic, rather than the needs of the people using the systems to manage their disease every day,” said Dachis. “We are excited to further empower One Drop users with this exciting addition to the One Drop experience.”
COPENHAGEN, Denmark – Liva Healthcare, a digital health platform for chronic disease management, has appointed Thomas Cooke as clinical services manager in the U.K. He was formerly the health and wellbeing manager at AXA PPP Proactive Healthcare. In his new role, Cooke will be responsible for delivering Liva Healthcare’s digital health care offering and supporting the company’s work with the NHS’s diabetes prevention program digital stream. He will oversee the health coaches that use Liva’s digital platform to monitor and communicate with their patients tackling Type 2 diabetes. “It’s an excellent time for Tom to join the team as we start to expand with new customers and reach the halfway point of the NHS: DPP digital pilot with patients showing fantastic results already,” said Simon Pickup, managing director at Liva Healthcare, in a statement. “Tom will help Liva expand in the U.K. during the next vital period of growth for the organization.”Liva is a digital health platform supported by a personal health coach to help patients reach their personal lifestyle goals, and prevent and manage chronic diseases such as Type 2 diabetes. In 2017, Liva was chosen as one of five technology providers to pilot the digital stream of the NHS: DPP.
SAN MATEO, Calif. – Evidation Health is partnering with Tidepool on a sleep pilot that will capture and study real world data from people with Type 1 diabetes.
The research will develop insights from data generated by continuous glucose monitors and insulin pumps, in addition to sleep and activity trackers from smartphones and other connected sensors.
Evidation Health helps life sciences and health care companies understand how everyday behaviors and health interact. Tidepool is an open source, not-for-profit company focused on making diabetes data more accessible, actionable and meaningful for people with diabetes, their care teams and researchers.
The observational study will explore the links between nocturnal hypoglycemia, next-day behavior, sleep patterns and heart rates to contribute to ongoing research on how everyday behavior data and diabetes complications interact.
“Linking real world data from connected devices with other medical data in virtual studies allow us to measure how behaviors—outside of the doctor’s office or hospital—affect health and impact outcomes,” said Deborah Kilpatrick, CEO of Evidation Health, in a statement. “Tidepool has done a fantastic job of giving people with diabetes access to their own data, and this effort provides a new opportunity to share everyday data with researchers at scale and enable more people to contribute to diabetes innovation.”
Tidepool joins a growing list of more than 100 individually permissioned data sources that are linked to Evidation’s platform, including Apple Health, Blue Button, Dexcom, Epic and Fitbit.
“People with diabetes can use their individual data to play a key role in improving health,” said Howard Look, president, CEO, and founder of Tidepool, in a statement. “Our study with Evidation gives people with diabetes a new way to share their data with researchers, and contribute to a better understanding of dangerous low-blood sugar levels, which can often occur more frequently while sleeping.”
Since 2012, Evidation Health has built a diverse virtual pool of research participants through its Achievement app, which currently has more than 2 million users.
KENILWORTH, N.J. – Healthy Interactions and Merck have launched map4health, a digital platform and mobile app designed to help improve the quality of diabetes patient support in between in-person coaching sessions. map4health enables patients to connect with educators through text and video-chat and provides weekly digital activities to sustain engagement. “We believe this tool will further enhance the positive impact that diabetes educators are making in the lives of their patients,” said Paul Lasiuk, co-founder and CEO of Healthy Interactions, a company that provides digital health engagement and education tools, in a statement. The map4health platform was developed as an extension of the companies’ Journey for Control collaboration, a patient-centric education initiative targeting diabetes educators and utilizing the U.S. Diabetes Conversation Map. Through the new platform, patients can securely log health information that their educators are able to review and respond to. “We are thrilled our work with Healthy Interactions will provide diabetes patients and educators a digital platform for dialogue and personalized self-management tools,” said Lisa French, associate vice president, strategy and commercial model innovation, at Merck, in a statement.
FAYETTEVILLE, Ark. – Medical technology company SFC Fluidics has announced a new Industry Discovery and Development Partnership supported by JDRF to develop an insulin patch pump with open-protocol communication capabilities. JDRF launched its Open-Protocol Automated Insulin Delivery (AID) Systems Initiative in 2017 with the goal of working with key stakeholders to understand the regulatory and liability implications of an “open-protocol” AID ecosystem and to accelerate the delivery of such components to market. “We are excited to support SFC in its open-protocol pump development as a key step toward the realization of our goal of an open-protocol AID ecosystem,” said Daniel Finan, JDRF research director, in a statement. “We are hopeful that solutions such as this will greatly expand choice in the marketplace, increase adoption of advanced, life-improving technologies among people with T1D, and accelerate the cadence of innovation in these treatment options.” The development and delivery to market of a fully interoperable, open-protocol insulin pump is the goal of this JDRF-SFC partnership. The two-year funding commitment from JDRF enables SFC to accelerate the development and regulatory submission of an open-protocol patch pump system that enables seamless, secure connectivity with other devices like interoperable continuous glucose monitors and third-party AID algorithms. SFC will develop a fully functional patch pump that will operate on its own platform, as well as publish its communication protocol, so that approved devices can communicate with the patch pump.